- Home
- GRI vs ATNF Comparison
GRI vs ATNF Comparison
Compare GRI & ATNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRI
- ATNF
- Stock Information
- Founded
- GRI 2018
- ATNF 2016
- Country
- GRI United States
- ATNF United States
- Employees
- GRI N/A
- ATNF N/A
- Industry
- GRI Biotechnology: Pharmaceutical Preparations
- ATNF Biotechnology: Pharmaceutical Preparations
- Sector
- GRI Health Care
- ATNF Health Care
- Exchange
- GRI Nasdaq
- ATNF Nasdaq
- Market Cap
- GRI 3.2M
- ATNF 3.8M
- IPO Year
- GRI N/A
- ATNF N/A
- Fundamental
- Price
- GRI $1.38
- ATNF $1.05
- Analyst Decision
- GRI Strong Buy
- ATNF
- Analyst Count
- GRI 2
- ATNF 0
- Target Price
- GRI $22.00
- ATNF N/A
- AVG Volume (30 Days)
- GRI 358.1K
- ATNF 43.3K
- Earning Date
- GRI 05-15-2025
- ATNF 05-15-2025
- Dividend Yield
- GRI N/A
- ATNF N/A
- EPS Growth
- GRI N/A
- ATNF N/A
- EPS
- GRI N/A
- ATNF N/A
- Revenue
- GRI N/A
- ATNF N/A
- Revenue This Year
- GRI N/A
- ATNF N/A
- Revenue Next Year
- GRI N/A
- ATNF N/A
- P/E Ratio
- GRI N/A
- ATNF N/A
- Revenue Growth
- GRI N/A
- ATNF N/A
- 52 Week Low
- GRI $1.10
- ATNF $0.66
- 52 Week High
- GRI $66.30
- ATNF $17.75
- Technical
- Relative Strength Index (RSI)
- GRI 39.90
- ATNF 49.77
- Support Level
- GRI $1.24
- ATNF $1.01
- Resistance Level
- GRI $1.49
- ATNF $1.10
- Average True Range (ATR)
- GRI 0.12
- ATNF 0.08
- MACD
- GRI 0.07
- ATNF -0.01
- Stochastic Oscillator
- GRI 59.52
- ATNF 35.29
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp was formed as a clinical-stage biotechnology company, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis by employing research, and, where appropriate, combination therapy. In addition, it has acquired certain source code and intellectual property relating to the back-end technology platform to operate an online blockchain casino, and moving forward, it plans to focus the majority of its operations on the creation of the online blockchain casino, while looking to monetize certain prior development-stage therapeutic product candidates for unmet medical needs. It has one reportable operating segment, iGaming.